Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02588131
Previous Study | Return to List | Next Study

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02588131
Recruitment Status : Unknown
Verified October 2015 by Italian Network for Tumor Biotherapy Foundation.
Recruitment status was:  Recruiting
First Posted : October 27, 2015
Last Update Posted : October 27, 2015
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Italian Network for Tumor Biotherapy Foundation

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : June 2016
Estimated Study Completion Date : March 2018
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):